Table 2

Duration of symptoms and postacute sequelae of COVID-19 (PASC) following breakthrough versus non-breakthrough COVID-19 infection

Breakthrough COVID-19 infection (N=116)Non-breakthrough COVID-19 infection (N=164)P value
Symptom-free days during 204-day* follow-up, mean133.8112.40.04
 Difference in symptom-free days (95% CI)21.40 (0.95 to 41.91)Reference0.04
CDC definition of PASC (COVID-19 symptoms lasting at least 28 days post-COVID-19 infection), n (%)48 (41)89 (54)0.04
 Unadjusted OR (95% CI)0.59 (0.37 to 0.96)Reference (1.0)0.03
 Adjusted OR (95% CI), Model 1†0.52 (0.31 to 0.86)Reference (1.0)0.01
 Adjusted OR (95% CI), Model 2†0.49 (0.29 to 0.83)0.01
WHO definition of PASC (COVID-19 symptoms lasting at least 90 days post-COVID-19 infection), n (%)‡10 (21)65 (41)0.01
 Unadjusted OR (95% CI)0.14 (0.07 to 0.30)Reference (1.0)<0.0001
 Adjusted OR (95% CI), Model 1†0.11 (0.05 to 0.24)Reference (1.0)<0.0001
 Adjusted OR (95% CI), Model 2†0.10 (0.04 to 0.22)Reference (1.0)<0.0001
  • *Primary follow-up period was 204 days, given that this was the maximum follow-up period among those with breakthrough infections

  • †Multivariable model one is adjusted for age, sex and race. Multivariable model two is adjusted for age, sex, race, comorbidity count and use of any one of the following medications: anti-CD20 monoclonal antibodies, methotrexate, mycophenolate or glucocorticoids.

  • ‡Denominator includes those who completed a survey at least 90 days following COVID-19 diagnosis; N=47 with breakthrough infection and 159 with non-breakthrough infection

  • CDC, Centres for Disease Control and Prevention; WHO, World Health Organization.